Search Results - "Borgstein, N.G"

P3.18 A Phase 1 multiple ascending dose study to assess the pharmacodynamic effects of ACE-031, an inhibitor of negative muscle regulators, in healthy volunteers by Borgstein, N.G, Barger, R, Yang, Y, Wilson, D.M, Haltom, E, Attie, K.M, Sherman, M.L

Get full text

M.P.1.03 Preliminary results from single subcutaneous administration of ACE-031, a form of the soluble activin type IIB receptor, in healthy postmenopausal volunteers by Borgstein, N.G, Condon, C.H, Yang, Y, Wilson, D.M, Haltom, E, Lachey, J.L, Seehra, J, Sherman, M.L

Get full text

465 DISCUSSION A Phase 1 dose escalating study of ACE-041, a novel inhibitor of ALK-1 mediated angiogenesis, in patients with advanced solid tumors by Sharma, S, Bendell, J.C, Hurwitz, H, Condon, C.H, Thornell, B.J, Slatcher, P.L, Borgstein, N.G, Sherman, M.L, Gordon, M.S

Get full text

No effect of amisulpride on lithium pharmacokinetics by Canal, M., Chaufour, S., Zieleniuk, I., Borgstein, N.G., Pinquier, J.L.

Get full text

Repeated administrations of amisulpride (A) do not modify lithium carbonate (L) pharmacokinetics in healthy volunteers by Chaufour, S., Borgstein, N.G., Van den Eynde, W., Bernard, F., Canal, M., Zieleniuk, I., Pinquier, J.L.

“…Clinical Pharmacology & Therapeutics (1999) 65, 143–143; doi:…”
Get full text

CABG, aspirin, and transfusion by Williams, S, Borgstein, N G, Gallandat Huet, R C

Get more information